{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T02:28:11Z","timestamp":1791167291913,"version":"4.1.0"},"reference-count":18,"publisher":"American Society of Hematology","issue":"4","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2013,1,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Recently, cereblon (CRBN) expression was found to be essential for the activity of thalidomide and lenalidomide. In the present study, we investigated whether the clinical efficacy of thalidomide in multiple myeloma is associated with CRBN expression in myeloma cells. Patients with newly diagnosed multiple myeloma were included in the HOVON-65\/GMMG-HD4 trial, in which postintensification treatment in 1 arm consisted of daily thalidomide (50 mg) for 2 years. Gene-expression profiling, determined at the start of the trial, was available for 96 patients who started thalidomide maintenance. In this patient set, increase of CRBN gene expression was significantly associated with longerprogression-free survival (P = .005). In contrast, no association between CRBN expression and survival was observed in the arm with bortezomib maintenance. We conclude that CRBN expression may be associated with the clinical efficacy of thalidomide. This trial has been registered at the Nederlands Trial Register (www.trialregister.nl) as NTR213; at the European Union Drug Regulating Authorities Clinical Trials (EudraCT) as 2004-000944-26; and at the International Standard Randomized Controlled Trial Number (ISRCTN) as 64455289.<\/jats:p>","DOI":"10.1182\/blood-2012-06-438101","type":"journal-article","created":{"date-parts":[[2012,12,12]],"date-time":"2012-12-12T02:36:48Z","timestamp":1355279808000},"page":"624-627","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":111,"title":["High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance"],"prefix":"10.1182","volume":"121","author":[{"given":"Annemiek","family":"Broyl","sequence":"first","affiliation":[{"name":"Department of Hematology, Erasmus MC, Rotterdam, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rowan","family":"Kuiper","sequence":"additional","affiliation":[{"name":"Department of Hematology, Erasmus MC, Rotterdam, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"van Duin","sequence":"additional","affiliation":[{"name":"Department of Hematology, Erasmus MC, Rotterdam, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bronno","family":"van der Holt","sequence":"additional","affiliation":[{"name":"HOVON Data Center Erasmus MC\u2013Daniel den Hoed, Rotterdam, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laila","family":"el Jarari","sequence":"additional","affiliation":[{"name":"HOVON Data Center Erasmus MC\u2013Daniel den Hoed, Rotterdam, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uta","family":"Bertsch","sequence":"additional","affiliation":[{"name":"Medizinische Klinik V, Universitaetsklinikum Heidelberg, Heidelberg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"Zweegman","sequence":"additional","affiliation":[{"name":"Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjan","family":"Buijs","sequence":"additional","affiliation":[{"name":"Departments of Medical Genetics and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Hose","sequence":"additional","affiliation":[{"name":"Medizinische Klinik V, Universitaetsklinikum Heidelberg, Heidelberg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henk M.","family":"Lokhorst","sequence":"additional","affiliation":[{"name":"Hematology, University Medical Center Utrecht, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartmut","family":"Goldschmidt","sequence":"additional","affiliation":[{"name":"Medizinische Klinik V, Universitaetsklinikum Heidelberg, Heidelberg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter","family":"Sonneveld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"24","key":"2019111809421262000_B1","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa043445","article-title":"Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.","volume":"352","author":"Richardson","year":"2005","journal-title":"N Engl J Med"},{"issue":"26","key":"2019111809421262000_B2","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa030288","article-title":"A phase 2 study of bortezomib in relapsed, refractory myeloma.","volume":"348","author":"Richardson","year":"2003","journal-title":"N Engl J Med"},{"issue":"21","key":"2019111809421262000_B3","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa070594","article-title":"Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.","volume":"357","author":"Dimopoulos","year":"2007","journal-title":"N Engl J Med"},{"issue":"21","key":"2019111809421262000_B4","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1056\/NEJMoa070596","article-title":"Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.","volume":"357","author":"Weber","year":"2007","journal-title":"N Engl J Med"},{"issue":"6","key":"2019111809421262000_B5","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1158\/1078-0432.CCR-10-1925","article-title":"Shifts in the therapeutic paradigm for patients newly diagnosed with multiple myeloma: maintenance therapy and overall survival.","volume":"17","author":"Palumbo","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"19","key":"2019111809421262000_B6","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1056\/NEJMoa1112704","article-title":"Continuous lenalidomide treatment for newly diagnosed multiple myeloma.","volume":"366","author":"Palumbo","year":"2012","journal-title":"N Engl J Med"},{"issue":"19","key":"2019111809421262000_B7","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1056\/NEJMoa1114138","article-title":"Lenalidomide maintenance after stem-cell transplantation for multiple myeloma.","volume":"366","author":"Attal","year":"2012","journal-title":"N Engl J Med"},{"issue":"3","key":"2019111809421262000_B8","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/nrclinonc.2012.15","article-title":"Latest advances and current challenges in the treatment of multiple myeloma.","volume":"9","author":"Mahindra","year":"2012","journal-title":"Nat Rev Clin Oncol"},{"issue":"5971","key":"2019111809421262000_B9","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1126\/science.1177319","article-title":"Identification of a primary target of thalidomide teratogenicity.","volume":"327","author":"Ito","year":"2010","journal-title":"Science"},{"issue":"18","key":"2019111809421262000_B10","doi-asserted-by":"crossref","first-page":"4771","DOI":"10.1182\/blood-2011-05-356063","article-title":"Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide.","volume":"118","author":"Zhu","year":"2011","journal-title":"Blood"},{"issue":"24","key":"2019111809421262000_B11","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1200\/JCO.2011.39.6820","article-title":"Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase 3 HOVON-65\/GMMG-HD4 trial.","volume":"30","author":"Sonneveld","year":"2012","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019111809421262000_B12","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1182\/blood-2011-09-379164","article-title":"Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p.","volume":"119","author":"Neben","year":"2012","journal-title":"Blood"},{"issue":"11","key":"2019111809421262000_B13","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/S1470-2045(10)70206-0","article-title":"Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65\/GMMG-HD4 trial.","volume":"11","author":"Broyl","year":"2010","journal-title":"Lancet Oncol"},{"issue":"20","key":"2019111809421262000_B14","doi-asserted-by":"crossref","first-page":"e175","DOI":"10.1093\/nar\/gni179","article-title":"Evolving gene\/transcript definitions significantly alter the interpretation of GeneChip data.","volume":"33","author":"Dai","year":"2005","journal-title":"Nucleic Acids Res"},{"key":"2019111809421262000_B15","first-page":"108","article-title":"PANP\u2013a new method of gene detection on oligonucleotide expression arrays.","author":"Warren","year":"2007"},{"issue":"14","key":"2019111809421262000_B16","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1182\/blood-2009-12-261032","article-title":"Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients.","volume":"116","author":"Broyl","year":"2010","journal-title":"Blood"},{"issue":"1","key":"2019111809421262000_B17","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2011-06-357038","article-title":"The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis.","volume":"119","author":"Morgan","year":"2012","journal-title":"Blood"},{"issue":"3","key":"2019111809421262000_B18","first-page":"287","article-title":"What is the functional role of the thalidomide binding protein cereblon?","volume":"2","author":"Chang","year":"2011","journal-title":"Int J Biochem Mol Biol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/121\/4\/624\/1367368\/zh800413000624.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/121\/4\/624\/1367368\/zh800413000624.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T10:37:03Z","timestamp":1574073423000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/121\/4\/624\/31240\/High-cereblon-expression-is-associated-with-better"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1,24]]},"references-count":18,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,1,24]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2012-06-438101","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,1,24]]}}}